Objective:

To evaluate the efficacy of combining recombinant human type III collagen dressings with advanced optimal pulse technology (AOPT) in treating rosacea.

Key Findings:

• Overall response rate at 12 weeks was 89.3% in the combination group vs 77.3% in the AOPT-alone group (p = 0.049).
• Combination therapy showed greater reductions in erythema, lesion severity, and pain scores.
• Quality of life improved more significantly in the combination group across various domains.
• Skin barrier measures favored the combination group, with decreased transepidermal water loss and increased hydration.
• Lower recurrence rates at 24 weeks: 14.7% in AOPT alone vs 2.7% in the combination group.

Interpretation:

Collagen dressings may enhance the short-term effectiveness of AOPT in treating rosacea, suggesting a multimodal approach could be beneficial.

Limitations:

• Modest sample size and single-center design.
• Relatively short follow-up period.
• Lack of histopathologic or molecular validation.
• Potential bias due to non-blinding of patients and operators.

Conclusion:

The combination of AOPT with collagen dressing offers superior benefits over AOPT alone, warranting further research in larger, multicenter trials.